$RAD — Latest Short Analysis
Assuming you mean Radiopharm Theranostics (ASX: RAD):
Approx. price: A$0.006
Market cap: ~A$26M
Catalyst: The company completed its FDA end-of-Phase 2 meeting for RAD101 on Oct. 5, 2026. (InvestSmart)
Positive: RAD101 Phase 2b data showed 93% concordance with MRI, supporting further development. (ADVFN)
Risk: RAD remains a very small, highly speculative biotech, with substantial recent price weakness. (InvestSmart)
Overall: 🟡 Speculative / High Risk — the clinical catalysts are encouraging, but funding, dilution, regulatory progress, and future trial results remain major risks.
Radiopharm Theranostics announcements
📊 Analysis Picture
View the RAD analysis picture
Informational only, not financial advice.
#BinanceLaunchesBinanceIntelligence #DubaiVARAIssuesReserveAssetAuditCircular #SECApproves3XBitcoinETF #WinklevossFilesSpotZcashETFApplication #IglooShutsDownAbstractBlockchain
Assuming you mean Radiopharm Theranostics (ASX: RAD):
Approx. price: A$0.006
Market cap: ~A$26M
Catalyst: The company completed its FDA end-of-Phase 2 meeting for RAD101 on Oct. 5, 2026. (InvestSmart)
Positive: RAD101 Phase 2b data showed 93% concordance with MRI, supporting further development. (ADVFN)
Risk: RAD remains a very small, highly speculative biotech, with substantial recent price weakness. (InvestSmart)
Overall: 🟡 Speculative / High Risk — the clinical catalysts are encouraging, but funding, dilution, regulatory progress, and future trial results remain major risks.
Radiopharm Theranostics announcements
📊 Analysis Picture
View the RAD analysis picture
Informational only, not financial advice.
#BinanceLaunchesBinanceIntelligence #DubaiVARAIssuesReserveAssetAuditCircular #SECApproves3XBitcoinETF #WinklevossFilesSpotZcashETFApplication #IglooShutsDownAbstractBlockchain
